Incidence and Prevalence of Retinal Vasculitis and Associated Autoimmune Comorbidities, Ocular Complications, and Treatment Patterns

Purpose To investigate the incidence, prevalence, associated conditions and therapeutic modalities of retinal vasculitis (RV).Methods Subjects diagnosed with RV in the TriNetX database between 2014 and 2024 were identified using the ICD-10 codes, excluding those with AIDS or HIV. The primary outcomes were the incidence and prevalence (annual and 10‑year cumulative). Demographic data, autoimmune comorbidities, immunosuppressive medication, ocular complications, and local ocular therapies at the time of or following diagnosis were collected for secondary analyses.Results From 114 907 642 subjects, 5342 cases of RV were identified. Demographic data included: 63.42% (N = 3387) women, 59.04% (N = 3154) White, 73.61% (N = 3932) Non-Hispanic or Latino and a mean age of 55 years (range 2–90). The most common autoimmune comorbidities were rheumatoid arthritis (3.88%, N = 199), sarcoidosis (3.48%, N = 179) and systemic lupus erythematosus (2.98%, N = 149). The most used systemic immunosuppressive medications were methotrexate (10.60%, N = 535), mycophenolate mofetil (9.88%, N = 502) and adalimumab (8.68%, N = 456). The most prevalent ocular complication was cystoid macular edema (21.06%, N = 956) and intravitreal injections (10.95%, N = 531) were the most frequently used procedure. Among the intravitreal agents, triamcinolone (7.07%, N = 362) was the most administered. Between 2014 and 2024, the incidence increased from 0.99 to 1.35 per 100 000 persons and the prevalence from 3.75 to 9.47 per 100 000 persons.Conclusion The rising incidence and prevalence of retinal vasculitis appear to be multifactorial, highlighting the need for interdisciplinary care, close monitoring and early intervention.

Authors

Institutions

Publication Details

Journal
Ocular Immunology and Inflammation
Published
2026-11-13
DOI
https://doi.org/10.1080/09273948.2026.2753545
Primary Topic
Ocular Diseases and Behçet’s Syndrome
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Incidence and Prevalence of Retinal Vasculitis and Associated Autoimmune Comorbidities, Ocular Complications, and Treatment Patterns

Meghan Berkenstock, Taulant Rama
1 links
Ocular Immunology and Inflammation
Ocular Diseases and Behçet’s Syndrome
article

Incidence and Prevalence of Retinal Vasculitis and Associated Autoimmune Comorbidities, Ocular Complications, and Treatment Patterns

Meghan Berkenstock, Taulant Rama
article en

Abstract

Purpose To investigate the incidence, prevalence, associated conditions and therapeutic modalities of retinal vasculitis (RV).Methods Subjects diagnosed with RV in the TriNetX database between 2014 and 2024 were identified using the ICD-10 codes, excluding those with AIDS or HIV. The primary outcomes were the incidence and prevalence (annual and 10‑year cumulative). Demographic data, autoimmune comorbidities, immunosuppressive medication, ocular complications, and local ocular therapies at the time of or following diagnosis were collected for secondary analyses.Results From 114 907 642 subjects, 5342 cases of RV were identified. Demographic data included: 63.42% (N = 3387) women, 59.04% (N = 3154) White, 73.61% (N = 3932) Non-Hispanic or Latino and a mean age of 55 years (range 2–90). The most common autoimmune comorbidities were rheumatoid arthritis (3.88%, N = 199), sarcoidosis (3.48%, N = 179) and systemic lupus erythematosus (2.98%, N = 149). The most used systemic immunosuppressive medications were methotrexate (10.60%, N = 535), mycophenolate mofetil (9.88%, N = 502) and adalimumab (8.68%, N = 456). The most prevalent ocular complication was cystoid macular edema (21.06%, N = 956) and intravitreal injections (10.95%, N = 531) were the most frequently used procedure. Among the intravitreal agents, triamcinolone (7.07%, N = 362) was the most administered. Between 2014 and 2024, the incidence increased from 0.99 to 1.35 per 100 000 persons and the prevalence from 3.75 to 9.47 per 100 000 persons.Conclusion The rising incidence and prevalence of retinal vasculitis appear to be multifactorial, highlighting the need for interdisciplinary care, close monitoring and early intervention.

Ocular Immunology and Inflammation
Johns Hopkins University (US), Drexel University (US)
Good health and well-being
Ocular Diseases and Behçet’s Syndrome
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon